Evidence map›Paper›PMID 26862994›Full record

ArticleEndocrinology2016

Development of a Quantitative PCR Assay for Detection of Human Insulin-Like Growth Factor Receptor and Insulin Receptor Isoforms.

Clare A Flannery, Anne M Rowzee, Gina H Choe, Farrah L Saleh, Caitlin C Radford, Hugh S Taylor, Teresa L Wood

Open access · bronzeAbstract read
In one paragraph

Article in Endocrinology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Clare A FlanneryDepartment of Obstetrics and Gynecology and Reproductive Sciences (C.A.F., G.H.C., F.L.S., C.C.R., H.S.T.), Yale School of Medicine, New Haven, Connecticut 06520; and Department of Pharmacology, Physiology, and Neuroscience and Cancer Center (A.M.R., T.L.W.), New Jersey Medical School, Rutgers University, Newark, New Jersey 07103.
Anne M RowzeeDepartment of Obstetrics and Gynecology and Reproductive Sciences (C.A.F., G.H.C., F.L.S., C.C.R., H.S.T.), Yale School of Medicine, New Haven, Connecticut 06520; and Department of Pharmacology, Physiology, and Neuroscience and Cancer Center (A.M.R., T.L.W.), New Jersey Medical School, Rutgers University, Newark, New Jersey 07103.
Gina H ChoeDepartment of Obstetrics and Gynecology and Reproductive Sciences (C.A.F., G.H.C., F.L.S., C.C.R., H.S.T.), Yale School of Medicine, New Haven, Connecticut 06520; and Department of Pharmacology, Physiology, and Neuroscience and Cancer Center (A.M.R., T.L.W.), New Jersey Medical School, Rutgers University, Newark, New Jersey 07103.
Farrah L SalehDepartment of Obstetrics and Gynecology and Reproductive Sciences (C.A.F., G.H.C., F.L.S., C.C.R., H.S.T.), Yale School of Medicine, New Haven, Connecticut 06520; and Department of Pharmacology, Physiology, and Neuroscience and Cancer Center (A.M.R., T.L.W.), New Jersey Medical School, Rutgers University, Newark, New Jersey 07103.
Caitlin C RadfordDepartment of Obstetrics and Gynecology and Reproductive Sciences (C.A.F., G.H.C., F.L.S., C.C.R., H.S.T.), Yale School of Medicine, New Haven, Connecticut 06520; and Department of Pharmacology, Physiology, and Neuroscience and Cancer Center (A.M.R., T.L.W.), New Jersey Medical School, Rutgers University, Newark, New Jersey 07103.
Hugh S TaylorDepartment of Obstetrics and Gynecology and Reproductive Sciences (C.A.F., G.H.C., F.L.S., C.C.R., H.S.T.), Yale School of Medicine, New Haven, Connecticut 06520; and Department of Pharmacology, Physiology, and Neuroscience and Cancer Center (A.M.R., T.L.W.), New Jersey Medical School, Rutgers University, Newark, New Jersey 07103.
Teresa L WoodDepartment of Obstetrics and Gynecology and Reproductive Sciences (C.A.F., G.H.C., F.L.S., C.C.R., H.S.T.), Yale School of Medicine, New Haven, Connecticut 06520; and Department of Pharmacology, Physiology, and Neuroscience and Cancer Center (A.M.R., T.L.W.), New Jersey Medical School, Rutgers University, Newark, New Jersey 07103.
Yale University · USRutgers, The State University of New Jersey · US

Funding

IGF and IGF Receptor Function in Mammary DevelopmentR01DK060612 · NIDDK · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI WOOD, TERESA L · 2002 to 2011
$2.8M
Environmental Estrogen Induced Epigenetic Alteration of Uterine Stem CellsR01HD076422 · NICHD · YALE UNIVERSITY · PI TAYLOR, HUGH SMITH · 2012 to 2016
$2.0M
Effect of Insulin on Estrogen Receptor Alpha Activity in Human Endometrial CellsK08HD071010 · NICHD · YALE UNIVERSITY · PI FLANNERY, CLARE ANN · 2012 to 2016
$658k
NICHD NIH HHS K08 HD071010NICHD NIH HHS K08HD071010NIDDK NIH HHS R01 DK060612NIDDK NIH HHS R01DK060612
6 · The paper itself

Abstract

The biological activity of insulin and the insulin-like growth factor (IGF) ligands, IGF-I and IGF-II, is based in part on the relative abundance and distribution of their target receptors: the insulin receptor (IR) splice variants A (IR-A) and B (IR-B) and IGF 1 receptor (IGF-1R). However, the relative quantity of all three receptors in human tissues has never been measured together on the same scale. Due to the high homology between insulin receptor (IR)-A and IR-B proteins and lack of antibodies that discern the two IR splice variants, their mRNA sequence is the most reliable means of distinguishing between the receptors. Hence, highly specific primers for IR-A, IR-B, and IGF-1R mRNA were designed to accurately detect all three receptors by quantitative RT-PCR and enable direct quantification of relative receptor expression levels. A standard concentration curve of cDNA from each receptor was performed. Assay specificity was tested using competition assays and postamplification analysis by gel electrophoresis and cloning. Forward and reverse primer concentrations were optimized to ensure equal efficiencies across primer pairs. This assay enables a specific molecular signature of IGF/insulin signaling receptors to be assayed in different tissues, cell types, or cancers.

Indexed as

AnimalsDNA PrimersHumansProtein IsoformsReceptor, IGF Type 1Receptor, InsulinReproducibility of ResultsReverse Transcriptase Polymerase Chain ReactionRNA, MessengerDNA PrimersProtein IsoformsReceptor, IGF Type 1Receptor, InsulinRNA, Messenger

Identifiers

PMID26862994
PMCPMC4816738
OpenAlexW2264243983

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.